<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_advanced" title="FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management" shortTitle="advanced" author="Isabelle Solassol, Frédéric Pinguet, Xavier Quantin" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/2218-273X/9/11/668/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
5.	NN	5.
</s>
<s type="frag">
Conclusions	NNS	conclusion
and	CC	and
Perspectives	NNS	perspective
</s>
</head>
<p>
<s type="decl">
EGFR-TKIs	NNP	EGFR-TKIs
are	VBP	be
currently	RB	currently
the	DT	the
standard	JJ	standard
first-line	JJ	first-line
treatment	NN	treatment
of	IN	of
patients	NNS	patient
with	IN	with
advanced	JJ	advanced
NSCLC	NNP	NSCLC
with	IN	with
activating	VBG	activate
<hi rend="italic">
EGFR	NNP	EGFR
</hi>
mutations	NNS	mutation
.	.	.
</s>
<s type="decl">
These	DT	this
targeted	VBN	target
therapies	NNS	therapy
are	VBP	be
usually	RB	usually
well	RB	well
tolerated	VBN	tolerate
comparative	JJ	comparative
to	IN	to
conventional	JJ	conventional
chemotherapy	NN	chemotherapy
.	.	.
</s>
<s type="decl">
The	DT	the
self-oral	JJ	self-oral
administration	NN	administration
of	IN	of
the	DT	the
drug	NN	drug
positively	RB	positively
contributes	VBZ	contribute
to	IN	to
improving	VBG	improve
patient	JJ	patient
compliance	NN	compliance
and	CC	and
reducing	VBG	reduce
the	DT	the
use	NN	use
of	IN	of
hospital	NN	hospital
resources	NNS	resource
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
this	DT	this
non-invasive	JJ	non-invasive
route	NN	route
of	IN	of
administration	NN	administration
is	VBZ	be
also	RB	also
associated	VBN	associate
with	IN	with
unpredictable	JJ	unpredictable
bioavailability	NN	bioavailability
,	,	,
increased	VBN	increase
risk	NN	risk
of	IN	of
drug	NN	drug
interactions	NNS	interaction
,	,	,
and	CC	and
concerns	NNS	concern
about	IN	about
patient	JJ	patient
safety	NN	safety
,	,	,
surveillance	NN	surveillance
,	,	,
and	CC	and
follow-up	NN	follow-up
.	.	.
</s>
<s type="frag">
Chronic	JJ	Chronic
EGFR-TKIs	NNP	EGFR-TKIs
</s>
<s type="decl">
underdosage	NN	underdosage
may	MD	may
favor	VB	favor
the	DT	the
selection	NN	selection
of	IN	of
resistant	JJ	resistant
clones	NNS	clone
and	CC	and
thus	RB	thus
disease	NN	disease
progression	NN	progression
,	,	,
and	CC	and
overdosage	NN	overdosage
may	MD	may
increase	VB	increase
the	DT	the
risk	NN	risk
of	IN	of
dose-related	JJ	dose-related
side	NN	side
effects	NNS	effect
.	.	.
</s>
<s type="decl">
Self-administration	NN	Self-administration
also	RB	also
means	VBZ	mean
that	IN	that
the	DT	the
severity	NN	severity
of	IN	of
side	NN	side
effects	NNS	effect
can	MD	can
be	VB	be
considerably	RB	considerably
impacted	VBN	impact
by	IN	by
patient	JJ	patient
behavior	NN	behavior
(	-LRB-	(
e.g.	FW	e.g.
,	,	,
dietary	NN	dietary
habits	NNS	habit
,	,	,
self-medicating	NN	self-medicating
,	,	,
smoker	NN	smoker
status	NN	status
)	-RRB-	)
.	.	.
</s>
<s type="decl">
To	IN	to
date	NN	date
,	,	,
EGFR-TKIs	NNPS	EGFR-TKIs
can	MD	can
be	VB	be
administered	VBN	administer
in	IN	in
advanced	JJ	advanced
NSCLC	NNP	NSCLC
for	IN	for
a	DT	a
long	JJ	long
period	NN	period
of	IN	of
time	NN	time
,	,	,
usually	RB	usually
until	IN	until
the	DT	the
disease	NN	disease
progresses	VBZ	progress
or	CC	or
unacceptable	JJ	unacceptable
toxicity	NN	toxicity
occurs	VBZ	occur
.	.	.
</s>
<s type="decl">
As	IN	as
early	JJ	early
intervention	NN	intervention
with	IN	with
supportive	JJ	supportive
care	NN	care
strategies	NNS	strategy
can	MD	can
minimize	VB	minimize
the	DT	the
intensity	NN	intensity
of	IN	of
adverse	JJ	adverse
reactions	NNS	reaction
or	CC	or
allow	VB	allow
for	IN	for
appropriate	JJ	appropriate
dose	NN	dose
adjustments	NNS	adjustment
without	IN	without
the	DT	the
need	NN	need
to	TO	to
discontinue	VB	discontinue
treatment	NN	treatment
,	,	,
acute	JJ	acute
toxicity	NN	toxicity
follow-up	NN	follow-up
and	CC	and
side	NN	side
effect	NN	effect
management	NN	management
is	VBZ	be
of	IN	of
major	JJ	major
interest	NN	interest
.	.	.
</s>
</p>
<p>
<s type="sub">
Therefore	RB	therefore
,	,	,
medical	JJ	medical
oncologists	NNS	oncologist
should	MD	should
not	RB	not
only	RB	only
understand	VB	understand
the	DT	the
AEs	NNS	ae
associated	VBN	associate
with	IN	with
these	DT	this
drugs	NNS	drug
,	,	,
but	CC	but
also	RB	also
develop	VB	develop
the	DT	the
necessary	JJ	necessary
skills	NNS	skill
to	TO	to
detect	VB	detect
and	CC	and
treat	VB	treat
them	PRP	they
to	TO	to
reduce	VB	reduce
morbidity	NN	morbidity
and	CC	and
mortality	NN	mortality
as	RB	as
well	RB	well
as	IN	as
premature	JJ	premature
discontinuation	NN	discontinuation
of	IN	of
treatment	NN	treatment
.	.	.
</s>
<s type="decl">
Patient	NN	patient
education	NN	education
on	IN	on
these	DT	this
strategies	NNS	strategy
is	VBZ	be
also	RB	also
of	IN	of
major	JJ	major
importance	NN	importance
and	CC	and
can	MD	can
improve	VB	improve
patient	JJ	patient
tolerance	NN	tolerance
,	,	,
quality	NN	quality
of	IN	of
life	NN	life
,	,	,
and	CC	and
overall	JJ	overall
treatment	NN	treatment
outcome	NN	outcome
by	IN	by
initiating	VBG	initiate
supportive	JJ	supportive
care	NN	care
soon	RB	soon
after	IN	after
symptoms	NNS	symptom
occur	VBP	occur
.	.	.
</s>
<s type="decl">
Within	IN	within
this	DT	this
guidance	NN	guidance
and	CC	and
preventive	JJ	preventive
strategy	NN	strategy
,	,	,
the	DT	the
pharmacist	NN	pharmacist
can	MD	can
play	VB	play
a	DT	a
major	JJ	major
role	NN	role
.	.	.
</s>
<s type="decl">
Good	JJ	good
knowledge	NN	knowledge
of	IN	of
disease	NN	disease
monitoring	NN	monitoring
,	,	,
response	NN	response
milestones	NNS	milestone
,	,	,
and	CC	and
the	DT	the
risks	NNS	risk
versus	IN	versus
benefits	NNS	benefit
of	IN	of
the	DT	the
treatment	NN	treatment
options	NNS	option
allows	VBZ	allow
pharmacists	NNS	pharmacist
to	TO	to
better	RBR	well
advise	VB	advise
patients	NNS	patient
or	CC	or
counsel	VB	counsel
patients	NNS	patient
more	RBR	more
effectively	RB	effectively
.	.	.
</s>
<s type="decl">
Nurses	NNS	nurse
and	CC	and
prescribers	NNS	prescriber
are	VBP	be
qualified	VBN	qualify
to	TO	to
monitor	VB	monitor
toxicity	NN	toxicity
risks	NNS	risk
as	RB	as
closely	RB	closely
as	IN	as
possible	JJ	possible
.	.	.
</s>
<s type="decl">
Unfortunately	RB	unfortunately
,	,	,
they	PRP	they
do	VBP	do
not	RB	not
necessarily	RB	necessarily
do	VB	do
so	RB	so
at	IN	at
regular	JJ	regular
intervals	NNS	interval
.	.	.
</s>
<s type="sub">
Patients	NNS	patient
can	MD	can
connect	VB	connect
with	IN	with
pharmacists	NNS	pharmacist
who	WP	who
can	MD	can
provide	VB	provide
them	PRP	they
additional	JJ	additional
information	NN	information
or	CC	or
complementary	JJ	complementary
recommendations	NNS	recommendation
on	IN	on
AEs	NNS	ae
without	IN	without
the	DT	the
need	NN	need
for	IN	for
patients	NNS	patient
to	TO	to
rapidly	RB	rapidly
contact	VB	contact
prescribers	NNS	prescriber
.	.	.
</s>
<s type="decl">
When	WRB	when
more	RBR	more
complex	JJ	complex
or	CC	or
serious	JJ	serious
AEs	NNS	ae
appear	VBP	appear
,	,	,
pharmacists	NNS	pharmacist
who	WP	who
work	VBP	work
closely	RB	closely
with	IN	with
nurses	NNS	nurse
and	CC	and
prescribers	NNS	prescriber
can	MD	can
propose	VB	propose
the	DT	the
most	RBS	most
appropriate	JJ	appropriate
therapeutic	JJ	therapeutic
strategies	NNS	strategy
.	.	.
</s>
<s type="multiple">
Finally	RB	finally
,	,	,
medical	JJ	medical
oncologists	NNS	oncologist
able	JJ	able
to	TO	to
understand	VB	understand
AEs	NN	ae
along	RB	along
with	IN	with
patient	JJ	patient
education	NN	education
and	CC	and
collaboration	NN	collaboration
between	IN	between
different	JJ	different
medical	JJ	medical
professional	JJ	professional
groups	NNS	group
for	IN	for
therapeutic	JJ	therapeutic
drug	NN	drug
monitoring	NN	monitoring
systems	NNS	system
are	VBP	be
needed	VBN	need
,	,	,
but	CC	but
further	JJR	further
research	NN	research
on	IN	on
the	DT	the
aforementioned	JJ	aforementioned
methods	NNS	method
of	IN	of
relief	NN	relief
for	IN	for
continued	VBN	continue
TKI	NNP	TKI
use	NN	use
should	MD	should
be	VB	be
also	RB	also
performed	VBN	perform
in	IN	in
the	DT	the
future	NN	future
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
importance	NN	importance
of	IN	of
proactive	JJ	proactive
patient	NN	patient
follow-up	NN	follow-up
must	MD	must
be	VB	be
emphasized	VBN	emphasize
rather	RB	rather
than	IN	than
relying	VBG	rely
on	IN	on
self-reporting	NN	self-reporting
between	IN	between
clinical	JJ	clinical
visits	NNS	visit
.	.	.
</s>
<s type="decl">
A	DT	a
randomized	JJ	randomized
trial	NN	trial
showed	VBD	show
that	IN	that
patients	NNS	patient
receiving	VBG	receive
chemotherapy	NN	chemotherapy
for	IN	for
advanced	JJ	advanced
cancer	NN	cancer
,	,	,
web-based	JJ	web-based
symptom	NN	symptom
reporting	NN	reporting
with	IN	with
automated	VBN	automate
clinician	NN	clinician
e-mail	NN	E-mail
alerts	NNS	alert
resulted	VBD	result
in	IN	in
better	JJR	good
health-related	JJ	health-related
quality	NN	quality
of	IN	of
life	NN	life
,	,	,
fewer	JJR	few
emergency	NN	emergency
room	NN	room
visits	NNS	visit
,	,	,
fewer	JJR	few
hospitalizations	NNS	hospitalization
,	,	,
and	CC	and
superior	JJ	superior
quality-adjusted	JJ	quality-adjusted
survival	NN	survival
.	.	.
</s>
</p>
<p>
<s type="decl">
Recently	RB	recently
,	,	,
Cheema	NNP	Cheema
et	FW	et
al.	FW	al.
assessed	VBD	assess
the	DT	the
impact	NN	impact
of	IN	of
an	DT	a
interprofessional	JJ	interprofessional
,	,	,
proactive	JJ	proactive
follow-up	NN	follow-up
algorithm	NN	algorithm
on	IN	on
the	DT	the
incidence	NN	incidence
of	IN	of
dose	NN	dose
interruptions	NNS	interruption
,	,	,
reductions	NNS	reduction
,	,	,
and	CC	and
the	DT	the
severity	NN	severity
of	IN	of
AEs	NNP	AEs
in	IN	in
patients	NNS	patient
on	IN	on
afatinib	NN	afatinib
.	.	.
</s>
<s type="decl">
The	DT	the
authors	NNS	author
reported	VBD	report
that	IN	that
over	IN	over
half	NN	half
of	IN	of
first	JJ	first
AEs	NNS	ae
and	CC	and
one	CD	one
third	NN	third
of	IN	of
all	DT	all
grade	NN	grade
1-2	CD	1-2
and	CC	and
grade	NN	grade
≥3	NN	≥3
AEs	NNS	ae
were	VBD	be
detected	VBN	detect
through	IN	through
proactive	JJ	proactive
follow-up	NN	follow-up
.	.	.
</s>
<s type="decl">
This	DT	this
multi-disciplinary	JJ	multi-disciplinary
AE	NN	AE
algorithm	NN	algorithm
resulted	VBD	result
in	IN	in
a	DT	a
low	JJ	low
rate	NN	rate
of	IN	of
costly	JJ	costly
emergency	NN	emergency
room	NN	room
or	CC	or
urgent	JJ	urgent
clinic	NN	clinic
visits	NNS	visit
and	CC	and
a	DT	a
reduced	VBN	reduce
incidence	NN	incidence
of	IN	of
severe	JJ	severe
drug-related	VBN	drug-relate
AEs	NNS	ae
and	CC	and
discontinuation	NN	discontinuation
therapy	NN	therapy
.	.	.
</s>
</p>
<p>
<s type="decl">
In	IN	in
conclusion	NN	conclusion
,	,	,
when	WRB	when
closely	RB	closely
monitoring	VBG	monitor
patients	NNS	patient
,	,	,
the	DT	the
ability	NN	ability
of	IN	of
clinicians	NNS	clinician
to	TO	to
make	VB	make
rapid	JJ	rapid
therapeutic	JJ	therapeutic
decisions	NNS	decision
in	IN	in
the	DT	the
event	NN	event
of	IN	of
medical	JJ	medical
complications	NNS	complication
is	VBZ	be
critical	JJ	critical
in	IN	in
the	DT	the
diagnosis	NN	diagnosis
and	CC	and
management	NN	management
of	IN	of
TKI-related	NN	tki-related
side	NN	side
effects	NNS	effect
.	.	.
</s>
<s type="decl">
This	DT	this
is	VBZ	be
even	RB	even
more	RBR	more
decisive	JJ	decisive
in	IN	in
the	DT	the
event	NN	event
of	IN	of
serious	JJ	serious
or	CC	or
even	RB	even
life-threatening	JJ	life-threatening
complications	NNS	complication
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
good	JJ	good
clinician	NN	clinician
–	:	-
patient	NN	patient
communication	NN	communication
,	,	,
drug	NN	drug
patient	NN	patient
education	NN	education
,	,	,
early	JJ	early
detection	NN	detection
and	CC	and
management	NN	management
of	IN	of
drug	NN	drug
side	NN	side
effects	NNS	effect
,	,	,
and	CC	and
monitoring	NN	monitoring
of	IN	of
disease	NN	disease
response	NN	response
with	IN	with
plasma	NN	plasma
concentration	NN	concentration
quantification	NN	quantification
can	MD	can
also	RB	also
improve	VB	improve
patient	NN	patient
outcomes	NNS	outcome
.	.	.
</s>
<s type="sub">
Close	JJ	Close
cooperation	NN	cooperation
between	IN	between
oncologists	NNS	oncologist
,	,	,
internists	NNS	internist
,	,	,
pharmaceutics	NNS	pharmaceutics
,	,	,
and	CC	and
nurses	NNS	nurse
should	MD	should
become	VB	become
the	DT	the
gold	NN	gold
standard	NN	standard
in	IN	in
the	DT	the
comprehensive	JJ	comprehensive
clinical	JJ	clinical
care	NN	care
of	IN	of
advanced	JJ	advanced
NSCLC	NNP	NSCLC
patients	NNS	patient
receiving	VBG	receive
TKIs	NNP	Tkis
.	.	.
</s>
</p>
</text>